Resources from the same session
455MO - NUC-7738 in patients with advanced solid tumours: Phase I results from the NuTide:701 phase I/II study
Presenter: Stefan Symeonides
Session: Mini Oral session: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
456MO - METEOR-1: A phase I study of the safety and efficacy of the protein arginine methyltransferase 5 (PRMT5) inhibitor GSK3326595 in advanced solid tumors
Presenter: Sophie Postel-Vinay
Session: Mini Oral session: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
Invited Discussant 455MO and 466MO
Presenter: Ulrik Lassen
Session: Mini Oral session: Developmental therapeutics
Resources:
Slides
Webcast
457MO - A phase I study of ATR inhibitor M1774 in patients with solid tumours (DDRiver Solid Tumours 301): Part A1 results
Presenter: Timothy Yap
Session: Mini Oral session: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
458MO - Efficacy of durvalumab (Durva) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic (met) cancers (Ca) (MEDIPAC)
Presenter: Joline Lim
Session: Mini Oral session: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
Invited Discussant 457MO and 458MO
Presenter: Irene Brana
Session: Mini Oral session: Developmental therapeutics
Resources:
Slides
Webcast
459MO - Phase Ia study to evaluate GDC-6036 monotherapy in patients with solid tumors with a KRAS G12C mutation
Presenter: Manish Patel
Session: Mini Oral session: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
460MO - Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers
Presenter: Komal Jhaveri
Session: Mini Oral session: Developmental therapeutics
Resources:
Abstract
Slides
Webcast